Cellectis Archives

Latest Posts

News and Trends 28 Jun 2017

UPDATE: The First Off-the-Shelf CAR-T Cancer Therapy has Entered the Clinic

Update (28/06/2017): Cellectis has announced the first administration of UCART123 in its Phase I trial in Acute Myeloid Leukemia. Update (07/02/2017): the FDA has granted Cellectis IND approval to start…

June 28, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 22 Dec 2016

The 10 Biggest Clinical Success Stories of 2016 in European Biotech

What are the most impressive advances in medical biotechnology this year? From cancer to peanut allergy, here's a list of the best success stories of 2016. Biotech is becoming a…

December 22, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 Dec 2016

What do the CAR-T Patient Deaths Mean for the Future of the Field?

Juno’s JCAR015 study came to a halt for the second time this year after two more patient deaths. But despite the bad news, hopes for CAR-T therapies remain high. Juno…

December 14, 2016 - 7 minutesmins - By Diana Kwon

News and Trends 5 Nov 2016

Would you Taste this Gene-Edited Dinner?

Genetic engineering can make food healthier, improve nutrition and reduce environmental impact. To demonstrate its potential, Cellectis hosted a dinner featuring futuristic food technology. Cellectis is a French company that…

November 5, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Sep 2016

Debunking the Immuno-Oncology Hype: is it as good as it sounds?

CAR-T therapies have gained plenty of attention lately by promising to end cancer with a one-off treatment. But all that glitters is not gold; experts remind us it is important to…

September 29, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

car t cd19 fda juno therapeutics cerebral edema

News and Trends 18 Jul 2016

UPDATED: Storm on the CAR-T field – 3 patients die in Phase II Study

A CAR-T program in Phase II trials (from Juno Therapeutics) was suspended by the FDA after 3 deaths, which could be treatment-related. How will this impact the field, given that…

July 18, 2016 - 5 minutesmins - By Denise Neves Gameiro

News and Trends 23 Jun 2016

Cellectis gets paid for a first Milestone, Investors are pleased

After successfully 'saving' two babies with terminal-stage acute Leukemia, Cellectis finally treated the first patient in its Phase I trial. A major milestone that could confirm the potential of its…

June 23, 2016 - 2 minutesmins - By Jerome Topsent

biotech nasdaq stock top biopharma finance 2016

News and Trends 23 Feb 2016

7 Trendy European Biotechs Listed on the NASDAQ in 2016

Here are 7 European Biotechs listed on the NASDAQ we thought were worth mentioning in more depth; location, market cap and brief financial and R&D backgrounds. NASDAQ is the second-largest Stock…

February 23, 2016 - 6 minutesmins - By Philip Hemme

DIRK BUSCH TECHNICAL UNIVERSITY MUNICH car t leukemia all

News and Trends 17 Feb 2016

Cancer: World Best Ever CAR-T Results have Just been Disclosed

These are the best results yet for CAR-T, this time from a research group led by Dirk Busch at the Technical University of Munich (Germany). In part backed by Juno Therapeutics, a method to…

February 17, 2016 - 3 minutesmins - By Denise Neves Gameiro

cellectis ucart19 nature cancer car t cell leukemia crs cytokine

News and Trends 12 Jan 2016

Cellectis has Discovered an ‘On-Switch’ to Make CAR-T Safer and Better Controlled

Cellectis researchers have managed to come up with a new CAR architecture with a small-molecule triggered 'on-switch', permitting better control and safety in CAR T-cell therapy, as published in Nature. As…

January 12, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 10 Dec 2015

Infographic: The Anatomy of European Biotech

Which part of our body do European biotechs prefer to target? And how diversified are the biotech companies in Europe nowadays? Let’s take the human body to know who works…

December 10, 2015 - 1 minutemin - By Nicolas Sainte-Foie

News and Trends 8 Feb 2016

The European Union Finances the Future of CAR-T Manufacturing

CAR-T is the way forward in Cancer therapeutics, which is one of the leading causes of Mortality in the Western world. Now this European consortium has amassed €6M for a…

February 8, 2016 - 3 minutesmins - By Dani Bancroft

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

Download Inpart’s latest report

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering